FBC
IONS icon

Fairfield, Bush & Co’s Ionis Pharmaceuticals IONS Stock Holding History

Fairfield, Bush & Co’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4
Closed -$202 – 275
2023
Q4 		$202 Buy
+4
New +$192 ﹤0.01% 511
2023
Q3 		– Sell
-4
Closed -$164 – 288
2023
Q2 		$164 Buy
+4
New +$154 ﹤0.01% 542
2022
Q3 		– Sell
-4
Closed – – 268
2022
Q2 		$0 Buy
+4
New +$151 ﹤0.01% 480

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fairfield, Bush & Co's IONS Position: Q1 2024 in Review

Fairfield, Bush & Co sold out of Ionis Pharmaceuticals (IONS) in Q1 2024, closing a stake of 4 shares — an estimated $202 sold.

Fairfield, Bush & Co first reported a position in IONS in Q2 2022 and held it in 3 quarters. The position peaked at $202 in Q4 2023. 361 funds tracked by Wall St. Rank hold IONS as of Q1 2024.

  • Fairfield, Bush & Co reported no remaining Ionis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Fairfield, Bush & Co sold 4 Ionis Pharmaceuticals shares in Q1 2024, an estimated $202.
  • Fairfield, Bush & Co first reported a position in Ionis Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • Fairfield, Bush & Co's Ionis Pharmaceuticals position peaked at $202 in Q4 2023.
  • 361 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2024.

Based on Fairfield, Bush & Co's 13F filing for Q1 2024, filed 15 May 2024.